“idiopathic-pulmonary-fibrosis” Archives

in
Entry Author Date Location
NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation 06/03/20 Boston
Pliant Therapeutics Prices IPO, Lands $144M to Test Fibrosis Drugs 06/03/20 San Francisco
Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies 05/12/20 San Francisco
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More 05/01/20 National
miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal 12/12/19 Boulder/Denver
Gilead Ups Stake in Galapagos With $5B Deal to Jumpstart Its R&D 07/15/19 San Francisco
West Coast Bio Roundup: CRISPR Patent, HCV Data, Verily Digs & More 02/19/16 San Francisco
Bristol-Myers Makes $150M Bet on Promedior, Fibrosis Drug 08/31/15 Boston
Tiger Teams, Dropping Subs, and Biotech’s Elusive Second Strikes 03/03/15 National
As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO 11/14/14 San Francisco
East Coast Biotech Roundup: Intercept, Idera, Inotek, & More 11/07/14 Boston
West Coast Biotech Roundup: Amgen, Inslee, Fibrogen, Receptos & More 10/30/14 Seattle
West Coast Biotech Roundup: Illumina, Atara, Invitae, Canaan & More 10/17/14 San Francisco
West Coast Biotech Roundup: ARCH, Ebola, ViaCyte, Calithera & More 08/28/14 San Francisco
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis? 08/25/14 San Francisco
Gilead Sciences Building on HIV, Becoming Cancer Drug Force 04/01/13 National
San Diego Life Sciences Roundup: Deals at MEI Pharma, Auspex, Ambit 11/09/12 San Diego
Promedior Moves Fibrosis Pipeline to Boston, Hires Shire Vet as CEO 05/15/12 Boston
Genoa Pharma Aims To Satisfy Big Pharma’s Hunger for IPF Drugs 03/30/12 San Diego
Biogen Idec Lets Stromedix Do The Hard Part 02/14/12 Boston
Biogen Buys Stromedix for $75M, Regaining Fibrosis Drug 02/14/12 Boston
Amira Pharma on How it Beat the Odds, and Sold an Early Stage Drug to Bristol-Myers for $325M 09/07/11 San Diego
UCSF Nabs $48M Gift 02/28/11 San Francisco
Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease 02/07/11 Boston
Gilead Buys Arresto for $225M 12/20/10 San Francisco
Amira Cuts Half of Staff, Scientific Founders Exit as Company Seeks to Conserve Cash 11/23/10 San Diego
Stromedix, with Biogen Idec Roots, Seeks Exit from Regulatory Limbo 07/20/10 Boston
Amira Mixes Small Biotech Irreverence, With Big Pharma Rigor, To Create New Lung Drugs 01/28/10 San Diego
Gilead Deepens Roots in Seattle, Seeks Long-Term Payoff From Lung Disease Research 01/13/10 Seattle
Page 1 of 1